ESCLEROSIS MÚLTIPLE
Vall d'Hebron Institut de Recerca
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Vall d'Hebron Institut de Recerca (10)
2024
-
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 95, Núm. 5, pp. 410-418
2022
-
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology
Multiple Sclerosis and Related Disorders, Vol. 63
-
Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis
Human Molecular Genetics, Vol. 31, Núm. 13, pp. 2155-2163
-
Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis
Journal of Neuroinflammation, Vol. 19, Núm. 1
2020
-
A new risk variant for multiple sclerosis at 11q23.3 locus is associated with expansion of CXCR5+ circulating regulatory T cells
Journal of Clinical Medicine, Vol. 9, Núm. 3
-
The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis
Cells, Vol. 9, Núm. 1
2019
-
Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis
Clinica Chimica Acta, Vol. 488, pp. 135-142
2015
-
Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice
Clinica Chimica Acta, Vol. 438, pp. 67-69
-
Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
Annals of Neurology, Vol. 77, Núm. 3, pp. 447-457
2011
-
Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice
Journal of Immunological Methods, Vol. 371, Núm. 1-2, pp. 170-173